Interferon-alpha in hepatitis C. Dosage, costs and benefits.
Briggs
A
A
Centre for Socio-Legal Studies, University of Oxford, England.
Shiell
A
A
D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D004305:Dose-Response Relationship, Drug; D006526:Hepatitis C / Q000191:economics / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000191:economics / Q000627:therapeutic use; D016898:Interferon-alpha / Q000191:economics* / Q000627:therapeutic use*; D011994:Recombinant Proteins